Background: Fabry disease (FD) is a rare hereditary lysosomal storage disease that has been highlighted as a possible etiology of stroke at a young age. Enlarged basilar artery diameters (BADs) have been demonstrated in FD, and we hypothesize that they might be useful for the screening of FD in young stroke patients. The aim of this study was to compare BADs of young stroke patients without FD to those of FD patients and of healthy age-matched controls. Methods: BADs were measured using MR angiography in 3 age- and gender-matched groups: 25 FD patients (aged 36.5 ± 11.0 years), 26 non-FD stroke patients and 20 healthy controls. Results: Compared to the non-FD stroke patients, FD patients had significantly enlarged BADs. FD patients could be significantly separated from stroke patients by BADs (area under the curve = 0.89, 95% confidence interval 0.81–0.98). Eighty-six percent of all subjects could be correctly classified by BADs (sensitivity 84%, specificity 88.5%). Conclusions: Enlarged BADs were able to detect FD within a cohort of FD, stroke patients and healthy controls. BAD measurement could be an easily obtainable and sensitive screening tool for FD in young stroke patients.

Keywords:
Basilar artery, Fabry disease, Young stroke patients
1.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999;281:249–254.
2.
Fellgiebel A, Muller MJ, Ginsberg L: CNS manifestations of Fabry’s disease. Lancet Neurol 2006;5:791–795.
3.
Mehta A, Ginsberg L: Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005;94(447):24–27, discussion 9–10.
4.
Sims K, Politei J, Banikazemi M, Lee P: Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788–794.
5.
Fellgiebel A, Keller I, Marin D, et al: Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63–68.
6.
Rolfs A, Bottcher T, Zschiesche M, et al: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794–1796.
7.
Brouns R, Thijs V, Eyskens F, et al: Belgian Fabry study: prevalence of Fabry disease in a cohort of 1,000 young patients with cerebrovascular disease. Stroke 2010;41:863–868.
8.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
9.
Whybra C, Kampmann C, Krummenauer F, et al: The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299–307.
10.
Albrecht J, Dellani PR, Muller MJ, et al: Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 2007;78:964–969.
11.
Mitsias P, Levine SR: Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8–17.
12.
Moore DF, Kaneski CR, Askari H, Schiffmann R: The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–263.
13.
Wozniak MA, Kittner SJ, Tuhrim S, et al: Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010;41:78–81.
14.
Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H: Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251:564–570.
15.
Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R: White matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231–240.
16.
Beck M, Ricci R, Widmer U, et al: Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838–844.
17.
Moore DF, Altarescu G, Ling GS, et al: Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525–531.
18.
Runck F, Steiner RP, Bautz WA, Lell MM: MR imaging: influence of imaging technique and postprocessing on measurement of internal carotid artery stenosis. AJNR Am J Neuroradiol 2008;29:1736–1742.
19.
Tarasow E, Abdulwahed Saleh Ali A, Lewszuk A, Walecki J: Measurements of the middle cerebral artery in digital subtraction angiography and MR angiography. Med Sci Monit 2007;13(suppl 1):65–72.
20.
Villablanca JP, Nael K, Habibi R, Nael A, Laub G, Finn JP: 3 T contrast-enhanced magnetic resonance angiography for evaluation of the intracranial arteries: comparison with time-of-flight magnetic resonance angiography and multislice computed tomography angiography. Invest Radiol 2006;41:799–805.
21.
Beckmann N, Stirnimann R, Bochelen D: High-resolution magnetic resonance angiography of the mouse brain: application to murine focal cerebral ischemia models. J Magn Reson 1999;140:442–450.
22.
Reese T, Bochelen D, Sauter A, Beckmann N, Rudin M: Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed 1999;12:189–196.
23.
Ballabio E, Bersano A, Bresolin N, Candelise L: Monogenic vessel diseases related to ischemic stroke: a clinical approach. J Cereb Blood Flow Metab 2007;27:1649–1662.
24.
Ikeda K, Nakamura Y, Hirayama T, et al: Cardiovascular risk and neuroradiological profiles in asymptomatic vertebrobasilar dolichoectasia. Cerebrovasc Dis 2010;30:23–28.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.